| Name | Title | Contact Details |
|---|
Royal Philips is a leading health technology company focused on improving people`s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips` health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries.
Scholten Surgical Insturments is a Lodi, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Covalent Medical Inc is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are an industry leader in the medical device market with a diverse product range including advanced automatic injection devices for drug delivery and innovative blood sampling products including lancets, lancing devices and safety lancets. Established in 1952 by Ivan Owen and John Mumford, we have almost 70 years of experience with offices, manufacturing sites and distributors located around the globe. Our corporate headquarters are located in Woodstock, Oxford UK. We are dedicated to providing innovative healthcare solutions for the management of a variety of medical conditions. With one of the most advanced global research, design and manufacturing capabilities that delivers innovation successfully to improve quality of life, encourage patient compliance, prevent infection and reduce healthcare costs; making a world of difference to a world of people.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe